The article outlines recent funding developments in the biotech and tech sectors, including Granite Bio's emergence with â¬87.6M to develop antibodies for inflammatory diseases, Didomi's â¬72M funding for enhancing user choice technology, and First Momentum Ventures' closing of â¬35M Fund II for early-stage investment in Industrial and Deep Tech. Additionally, Oryzon Genomics successfully raised â¬30M to advance its epigenetic research. These updates underline the rapid innovation and investment in these industries.
Granite Bio, armed with â¬87.6M funding, aims to create groundbreaking antibodies addressing inflammatory and autoimmune conditions, marking a significant advancement in biotech.
Didomi's â¬72M funding from Marlin Equity partners will enhance its technology to help organizations optimize user choice and streamline marketing across multiple platforms.
First Momentum Ventures has successfully closed its â¬35M Fund II to support early-stage startups in Industrial Tech and Deep Tech, fostering innovation in Europe.
Oryzon Genomics, a clinical-stage biopharmaceutical firm, has recently completed a â¬30M capital raise to further its research in epigenetics, indicating ongoing growth in biopharmaceuticals.
Collection
[
|
...
]